From around September of last year right up until the ball dropped New Year’s Eve, you couldn’t go a day without hearing someone lament just how terrible the year wound up being. From celebrity deaths and other shocking world events to an increasingly hostile political environment, 2016 was the year that everyone simply wanted to forget.
The corporate world had its share of upheaval as well, but continue reading...
“A recent study indicated…” The phrase is used to introduce countless articles that report on the medical industry. This blog is no exception. Savvy consumers always have to be aware, however, of how those studies came to be. Who funded them? What was the exact question they sought to answer? What, if any, possible ulterior motives could exist for the creation of such a study? Information is there to be ...
Reuters reports that andexanet alfa, a drug developed by Portola Pharmaceuticals to reverse the bleeding side effects of new oral anticoagulants like Xarelto, has proven successful in a late-stage clinical trial. Portola hopes the new data will help earn the antidote approval from the U.S. Food and Drug Administration.
Xarelto is a relatively new blood thinner that has made strides in the pharmaceutical industry since its introduction in 2011. ...
continue reading...Judge Eldon Fallon of the U.S. District Court for the Eastern District of Louisiana has assigned early 2017 trial dates for the first four federal Xarelto lawsuits, Reuters reports. Currently, over 1,700 Xarelto bleeding lawsuits are pending in the Louisiana Xarelto MDL.
Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2011 for use as an anticoagulant in certain patients at risk for embolic events. ...
continue reading...Finanzen reports that the anticoagulant Xarelto has been approved by the Japanese Ministry of Health, Labor, and Welfare for the treatment and secondary prevention of thromboembolism and deep vein thrombosis. Xarelto was already approved in Japan for prevention of stroke in patients with nonvalvular atrial fibrillation.
The U.S. Food and Drug Administration approved Xarelto in 2011 for treatment of pulmonary embolism and deep vein thrombosis in certain patients. Xarelto ...
continue reading...The number of Xarelto lawsuits in federal court jumped by nearly 500 over the month of August. There are currently over 1,700 Xarelto lawsuits consolidated in a multidistrict litigation in the U.S. District Court for the Eastern District of Louisiana, and if recent court records are anything to go by, the number will continue to increase rapidly in the coming months.
Xarelto is a blood-thinning drug approved by ...
continue reading...
